A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial
- 1 December 2006
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 368 (9553) , 2125-2135
- https://doi.org/10.1016/s0140-6736(06)69861-9
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
This publication has 17 references indexed in Scilit:
- Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trialThe Lancet, 2006
- Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral TherapyHIV Research & Clinical Practice, 2005
- Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER CohortJournal of Antimicrobial Chemotherapy, 2005
- Efficacy and Safety of Abacavir Plus Lamivudine Versus Didanosine Plus Stavudine When Combined with a Protease Inhibitor, a Nonnucleoside Reverse Transcriptase Inhibitor, or Both in HIV-1 Positive Antiretroviral-Naive PersonsHIV Research & Clinical Practice, 2004
- Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppressionAIDS, 2004
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 2003
- Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nonnucleoside Reverse Transcriptase InhibitorsAIDS Research and Human Retroviruses, 2002
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Decreased HIV-Associated T Cell Apoptosis by HIV Protease InhibitorsAIDS Research and Human Retroviruses, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999